Stay updated on Amgen Press Releases

Sign up to get notified when there's something new on the Amgen Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Amgen Press Releases page

  1. Check
    today
    Change Detected
    Summary
    In June 2024, the FDA approved Blincyto® for treating CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia, while Amgen announced positive results for Uplizna® in treating IgG4-related disease and plans to present innovative rheumatology research at EULAR 2024.
    Difference
    100%
    Check dated 2024-07-26T17:00:59.000Z thumbnail image
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    Amgen has made significant advancements, including the FDA approval of Blincyto for B-ALL and Imdelltra for small cell lung cancer, alongside positive trial results for Uplizna in IgG4-RD, while also announcing multiple upcoming presentations at major healthcare conferences.
    Difference
    100%
    Check dated 2024-07-22T13:15:28.000Z thumbnail image
  6. Check
    7 days ago
    Change Detected
    Summary
    In June 2024, the FDA approved Blincyto® for treating CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia, while Amgen announced positive Phase 3 trial results for Uplizna® and plans to present innovative rheumatology research at EULAR 2024.
    Difference
    100%
    Check dated 2024-07-20T10:15:25.000Z thumbnail image
  7. Check
    8 days ago
    Change Detected
    Summary
    The FDA approved Blincyto (blinatumomab) for the treatment of B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, marking a significant advancement in leukemia treatment.
    Difference
    100%
    Check dated 2024-07-19T09:04:36.000Z thumbnail image
  8. Check
    9 days ago
    Change Detected
    Summary
    FDA approves Blincyto (blinatumomab) in CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, Amgen presents innovative rheumatology research at EULAR 2024, Amgen announces positive results for phase 3 registrational trial evaluating Uplizna (inebilizumab-CDON) for treatment of immunoglobulin G4-related disease (IgG4-RD), New data presented at ATS 2024 show the potential of Tezspire to help patients living with COPD, FDA approves Imdelltra (tarlatamab-dlle), the first and only T-cell engager therapy for the treatment of extensive-stage small cell lung cancer.
    Difference
    100%
    Check dated 2024-07-18T07:22:32.000Z thumbnail image
  9. Check
    12 days ago
    Change Detected
    Summary
    The FDA approved Blincyto in the consolidation phase for B-ALL, Amgen presented innovative rheumatology research at EULAR 2024, and positive results were announced for the phase 3 trial of Uplizna for IgG4-RD.
    Difference
    100%
    Check dated 2024-07-15T05:48:48.000Z thumbnail image

Stay in the know with updates to Amgen Press Releases

Enter your email address, and we'll notify you when there's something new on the Amgen Press Releases page.